Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form

Transfusion

Volumn 44, Issue 9, 2004, Pages 1344-1349

  Marín Y López, Rafael Antonio ^b   Romero Estrella, Sagrario ^b   Infante Ramírez, Lilia ^b   Méndez Aquino, Jorge Saúl ^b   Berrón Ruiz, Patricia ^b   Morales Alfaro, Norma Angélica ^b   Vivar, Raúl ^b   Carrada, Etelvina ^b   Del Refugio Rivera Rendón, María ^b   Sánchez Guerrero, Sergio Arturo ^a  

^a Ctro Nac de la Transfus Sanguinea   (Mexico)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIAGNOSTIC TEST; ELECTROIMMUNOASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOBLOTTING; INFECTION RISK; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID TEST; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDY; SCREENING TEST; SELF CARE; SELF EXCLUSION FORM; SEROPREVALENCE; SIGNAL NOISE RATIO; STATISTICAL ANALYSIS;

ADULT; BLOOD DONORS; DNA, VIRAL; FEMALE; HEPATITIS C; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; INFORMED CONSENT; MALE; MASS SCREENING; MEDICAL RECORDS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SELF DISCLOSURE; SEROEPIDEMIOLOGIC STUDIES; VIREMIA;

EID: 4344667465     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.03379.x     Document Type: Article

References (14)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
2. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV and HBV in whole blood donations. Transfusion 2003;43:721-9.
3. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
4. Busch MP, Dodd RY. NAT and blood safety: what is the paradigm? Transfusion 2000;40:1157-60.
5. Couroucé AM, Le Marrec N, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 2000;40:1198-202.
6. Klein HG. Will blood transfusion ever be safe enough? JAMA 2000;2:238-40.
7. Transfusion medicine in the Americas 1994-2000. OPS/HSE-LAB/04. Washington: Panamerican Health Organization, World Health Organization, 2001.
8. Norma Oficial Mexicana NOM-003-SSA2-1993, For the collection and handling of human blood components for therapeutical purposes. México, 1993.
9. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and results reporting of antibody to hepatitis C virus. MMWR 2003;52(RR03):1-16.
10. Colton T. Statistics in medicine. Boston: Little Brown, 1979.
11. Swartz MH. Textbook of physical diagnosis. History and examination, 3rd ed. Philadelphia: W.B. Saunders, 1998:3-26.
12. Lefrère JJ, Elghouzzi MH, Duc A, et al. Interviews of individuals diagnosed as anti-human immunodeficiency virus-positive through the screening of blood donations in the Paris area from 1991 to 1994: reflections on the selection of blood donors. Transfusion 1996;36:124-7.
13. Kleinman S. Donor selection and screening procedures. In: Nance ST, ed. Blood safety current challenges. Bethesda: American Association of Blood Banks, 1992:169-200.
14. Making the difference: volunteer, non-remunerated donor recruitment, 1st ed. El Salvador: WHO, PAHO, and the International Federation of Red Cross and Crescent Red Societies, 2002.